Endothelium, thrombosis and fibrinolysis;ENDOTHELIUM, THROMBOSE ET FIBRINOLYSE

Revue du Praticien

Volumn 47, Issue 20, 1997, Pages 2227-2231

  Alessi, Marie Christine ^a   Juhan Vague, Irène ^a  

^a TIMONE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR;

ANGIOGENESIS; BLOOD CLOTTING; ENDOTHELIUM; FIBRINOLYSIS; HUMAN; SHORT SURVEY; THROMBOSIS; VASCULAR ENDOTHELIUM; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; THROMBOCYTE;

BLOOD COAGULATION; BLOOD PLATELETS; ENDOTHELIUM, VASCULAR; FIBRINOLYSIS; HUMANS; PLASMINOGEN ACTIVATORS; PLASMINOGEN INACTIVATORS; THROMBOSIS;

EID: 0031573735     PISSN: 00352640     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (36)

1. Demuth K, Myara I, Moatti N. Biologie de la cellule endothéliale et athérogenèse. Ann Biol Clin 1995; 53 : 171-89.
2. Astrup T. Biological significance of fibrinolysis. Lancet 1956; ii : 565-8.
3. Copley AL. Fibrinolysis and atherosclerosis. Lancet 1957; i: 102-03.
4. Bachmann F. The plasminogen plasmin enzyme system. Hemostasis and Thrombosis : Basic principles and Clinical Practice. Third Edit edited by Colman RW, Hirsh J, Marder VJ, and Salzman EW. J.B. Lippincott Company, Philadelphia, 1994, Chapter 84, pp 1592.
5. Keber D, Stegnar M, Kluft C. Different tissue plasminogen activator release in the arm and leg during venous occlusion is equalized after DDAVP infusion. Thromb Haemostas 1990; 63 : 72-5.
6. Carmeliet P, Schoonjans L, Kieckens L et al. Physiological consequences of loss of plasminogen activator gene function in mice. Nature 1994; 368 : 419-24.
7. Samama M. Hypofibrinolysis and venous thrombosis. Thrombosis : An update. In : Neri Serneri GG, Gensini GF, Abbate R, Frisco D (eds). Florence, Scientific Press, 1992 : 165-81.
8. Jansson JH, Nilsson TK, Olofsson BO. Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris. Eur Heart J 1991; 12 : 157-61.
9. Thompson SG, KienastJ, Pyke SDM, Haverkate F, van de Loo JCW. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995; 332 : 635-41.
10. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue type plasminogen activator and risk of myocardial infarction. Lancet 1993; 341 : 1165-8.
11. Juhan-Vague I, Pyke SDM, Alessi MC, Jespersen J, Haverkate F., Thompson SG Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. Circulation 1996; 94 : 2057-63.
12. Padro T, Emeis JJ, Steins M, Schmid KW, Kienast J. Quantification of plasminogen activators and their inhibitors in the aortic vessel wall in relation to the presence and severity of atherosclerotic disease. Arterioscler Thromb Vase Biol 1995; 15 : 893-902
13. Pepper MS, Vassalli JD, Montesano R, Orci L Urokinase type plasminogen activator is induced in migrating capillary endothelial cells. J Cell Biol 1987; 105 : 2535-41.
14. Grau E, Moroz LA. Fibrinolytic activity of normal human blood monocytes. Thromb Res 1989; 53 : 145-9.
15. Jiang Y, Pannell R, Liu JN, Gurewich V. Evidence for a novel binding protein to urokinase-type plasminogen activator in platelet membranes. Blood 1996; 7 : 2775-81.
16. Schneiderman J, Sawdey SM, Keeton MR et al. Increased type I plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci USA 1992; 89 : 6998-7002.
17. Chomiki N, Henry M, Alessi MC, Anfosso F, Juhan-Vague I. Plasminogen activator inhibitor I expression in human liver and healthy or atherosclerotic vessel walls. Thromb Haemost 1994; 72 : 44-53.
18. Biemond BJ, Levi M, Corinel R, Janse MJ, ten Cate JW, Pannekoek H. Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis. Effects of a plasminogen activator inhibitor type I neutralizing monoclonal antibody. Circulation 1995; 91 : 1175-81.
19. Marsh JJ, Konopka RG, Lang IM et al. Suppression of thrombolysis in a canine model of pulmonary embolism. Circulation 1994; 90 : 3091-7.
20. Carmeliet P, Kiecknens L, Schoonjans L et al. Plasminogen activator I gene deficient mice. J Clin Invest 1993; 92: 2746-55.
21. Tanaka K, Sueishi K. Biology of disease. Lab Invest 1993; 69 : 5-18.
22. Hamsten A, De Faire U, Walldius G et al., Plasminogen activator inhibitor in plasma : risk factor for recurrent myocardial infarction. Lancet 1987; 11: 3-9.
23. Shimomura I, Funahashi T, Takahashi M et al. Enhanced expression of PAI-1 in visceral fat : Possible contributor to vascular disease in obesity. Nature Med 1996; 2: 800-3.
24. Alessi MC, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-Vague I. Production of plasminogen activator inhibitor I by human adipose tissue. Possible link between visceral fat accumulation and vascular disease. Diabetes 1997 ; 46: 860-7.
25. Eriksson P, Kallin B, van't Hooft FM, Bavenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor I gene is associated with myocardial infarction. Proc Natl Acad Sci USA 1995; 92 : 1851-5.
26. Ye S, Green FR, Scarabin PY et al. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator Inhibitor-1 (PAI-1) associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Thromb Haemostas 1995; 74: 837-41.
27. Hajjar KA, Harpel PC, Jaffe EA, Nachman RL, Binding of plasminogen to cultured human endothelial cells. J Biol Chem 1986; 261 : 11656-62.
28. Hajjar KA, Harpel PC, Nachman RL Binding of tissue plasminogen activator to cultured human endothelial cells. J Clin Invest 1987; 80: 1712-5.
29. Hajjar KA, Jacovina AT, Chacko J. An endothelial cell receptor for plasminogen/tissue plasminogen activator. J Biol Chem 1994; 269 : 21191-7.
30. McLean JW, Tomlinson JE, Kuang WJ et al. DNA sequence of human apolipoprotein (a) is homologous to plasminogen. Nature 1987; 330: 132-7.
31. Rhoads GG, Dahlen G, Berg K, Morton NE, Dannenberg AL Lp(a) lipoprotein as a risk factor for myocardial infarction. JAMA 1986; 256 : 2540-5.
32. Nachman RL Thrombosis and atherogenesis: molecular connections. Blood 1992; 79 : 1897-906.
33. Milles LA, Fless GM, Levin EG, Scanu AM, Plow EF. A potential basis for the thrombotic risks associated with lipoprotein (a). Nature 1989; 339 : 301-3.
34. Anglés-Cano E. Overview on fibrinolysis: plasminogen activation pathways on fibrin and cell surfaces. Chem Phys Lipids 1994; 67/68: 353-62.
35. Maeda S, Abe A, Sashima M, Makwo K, Noma A, Kawade M. Transient changes of serum lipoprotein (a) as an acute phase protein. Atherosclerosis 1989; 78 : 145-8.
36. Etinger O, Hajjar DP, Hajjar KA, Harpel PC, Nachman RL Lipoprotein (a) regulates plasminogen activator inhibitor I expression in endothelial cells. J Biol Chem 1989; 266 : 2459-64.